Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to examine whether Right Unilateral Low-Amplitude Pulse - Seizure Therapy (RUL LAP-ST) treatment has more magnitude and rate of remission of SI as conventional pulse amplitude Right Unilateral Electroconvulsive Therapy (RUL ECT) (based on our prior secondary analysis). Our central hypothesis is that RUL LAP-ST has significantly less…
Conditions studied
Suicidal Ideation, Major Depressive Disorder, Schizo Affective Disorder, Bipolar Disorder
About this study
This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to examine whether Right Unilateral Low-Amplitude Pulse - Seizure Therapy (RUL LAP-ST) treatment has more magnitude and rate of remission of SI as conventional pulse amplitude Right Unilateral Electroconvulsive Therapy (RUL ECT) (based on our prior secondary analysis). Our central hypothesis is that RUL LAP-ST has significantly less cognitive/memory side effects (no memory side effects were noted in our prior studies for 500mA and 600mA) and thus is more favorable in terms of side effects compared to RUL conventional pulse amplitude ECT, while maintaining better anti-suicidal effect.
Interventions
- Device: Sigma-Stim — Right Ultra-Brief Low Amplitude Seizure Therapy at 600mA or 700mA vs Right Unilateral Ultra-Brief Standard ECT at 800mA.
- Procedure: RUL LAP-ST (Low-Amplitude Pulse Seizure Therapy - Right Unilateral) — Please see description above
Primary outcomes
- Suicide Ideation - Self Report (Through study completion, an average of four weeks)
- Suicide Ideation - Clinician Rated (Through study completion, an average of four weeks)
Eligibility information
Study locations
- Pine Rest Christian Mental Health Services, Grand Rapids, Michigan 49548 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.